Longeveron shares surge 31.64% intraday after Alzheimer's treatment trial results and $15M funding boost.

Longeveron Inc. (NASDAQ: LGVN) surged 31.64% intraday trading on March 13, 2026, driven by positive developments in its Alzheimer’s treatment pipeline and strategic leadership changes. The stock’s sharp rise followed reports of promising Phase 2 clinical trial results for laromestrocel, which demonstrated improved physical function in age-related frailty patients over nine months. Additionally, a $15M private placement, expandable to $30M based on trial success, bolstered financial stability. The appointment of Stephen Willard, a biotech industry veteran, as CEO further reinforced investor confidence, signaling stronger trial management and business development focus. These catalysts aligned with market optimism over the company’s therapeutic potential and operational resilience.